Physician profile
Mark Aronov
NPI 1730390212
$8,023.14
in general payments reported to CMS, 2019-2025
36 companies · $3,535 in 2025
The $3,535 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.90 · 2021: $307 · 2022: $1,020 · 2023: $1,663 · 2024: $1,463 · 2025: $3,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,147 · Consulting Fee: $1,500 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,147.20 |
| Consulting Fee | $1,500.00 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,290.01 | 2021-2025 | |
| Novo Nordisk INC | $1,100.19 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $593.67 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $578.66 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Gilead Sciences, INC. | $456.47 | 2023-2025 | Yeztugo, Descovy |
| Glaxosmithkline, LLC. | $440.41 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $349.36 | 2022-2025 | |
| Abbvie INC. | $338.23 | 2021-2025 | Vraylar, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $239.94 | 2022-2025 | |
| Astellas Pharma US INC | $235.25 | 2022-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.61 | 2022-2025 | Jardiance, Ofev, Spiriva Respimat |
| Biohaven Pharmaceutical Holding Company Ltd. | $127.45 | 2022 | |
| Amgen INC. | $124.66 | 2022-2025 | Repatha, Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $94.33 | 2021-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $87.66 | 2022-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $76.26 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $66.49 | 2021-2025 | Freestyle Libre 3 |
| Inari Medical, INC. | $65.77 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Exact Sciences Corporation | $63.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $58.95 | 2022-2024 | Xarelto |
| Shield Therapeutics INC | $46.36 | 2022-2024 | Accrufer |
| Idorsia Pharmaceuticals US INC | $44.92 | 2023 | Quviviq |
| Corcept Therapeutics | $44.30 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $42.41 | 2025 | Gvoke Hypopen |
| Medtronic USA, INC. | $35.90 | 2019 | |
| Currax Pharmaceuticals LLC | $29.22 | 2023-2025 | Contrave |
| Alfasigma USA, INC. | $26.33 | 2022 | |
| Mylan Specialty L.P. | $22.91 | 2024 | Yupelri |
| Esperion Therapeutics, INC. | $22.41 | 2025 | Nexletol |
| Insulet Corporation | $20.41 | 2023 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $20.30 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $19.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.16 | 2025 | Xifaxan |
| Orthofix Medical, INC. | $15.90 | 2022 | |
| Amarin Pharma, INC. | $14.63 | 2022 | |
| Viatris Specialty LLC | $13.68 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Aronov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.